Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis...
Leadership
Michael Cloonan M.B.A.
President, CEO & Director
Elena H. Ridloff C.F.A.
Chief Financial Officer
Caroline Stark Beer M.B.A.
Chief Business Officer
Greg Hurlbut Ph.D.Founder
Co-Founder & Senior VP of Discovery Research
Mark Munson Ph.D.Founder
Co-founder & Senior VP of Medicinal Chemistry
Meghan Bagshaw
Vice President of Programs, Portfolio & Operations
